Nexpring Health

Nexpring Health, based in the US, is focused on enhancing fertility treatments through advanced reproductive technologies that improve the efficiency and effectiveness of assisted reproductive processes. Nexpring Health specializes in reproductive health solutions aimed at fertility enhancement. Founded in 2025 in Beverly, US by Astorg, the company has undergone significant transformations, including the acquisition of Hamilton Thorne's reproductive health division in November 2024 and FUJIFILM Irvine Scientific, Inc. 's medical media unit in June 2025.

These strategic moves support its operational capabilities and expansion in the fertility sector. The company has completed 1 deal to date, with its most recent deal occurring on November 29, 2024. Nexpring Health specializes in advanced reproductive technologies, focusing on products and services that enhance the efficiency and effectiveness of fertility treatments. The company’s core offerings include innovative solutions for embryologists, clinicians, and fertility clinics, designed to address the complexities of assisted reproductive technology (ART).

Key products, such as specialized media for embryo development, advanced catheter systems for embryo transfer, and precision laser technologies like the Lykos laser, facilitate critical processes in In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). These products serve a diverse client base, including fertility clinics and healthcare providers engaged in reproductive medicine across North America, Europe, and Asia, aiming to improve outcomes for patients experiencing infertility challenges. Nexpring Health generates revenue through direct partnerships with fertility clinics and healthcare providers, leveraging a business-to-business (B2B) model for its product distribution. The company’s offerings, including proprietary solutions for embryo handling and cryopreservation, are structured around transactional agreements that may involve bulk purchases and ongoing service contracts.

Fertility clinics procure specialized media and equipment as part of a subscription model, ensuring they are equipped with the latest advancements in reproductive technology. The pricing structure for these products reflects the high value and precision required in fertility treatments, aligning with the critical nature of the services provided to patients. Each of these offerings is integral to Nexpring Health's operational model, contributing to a steady revenue stream while supporting the mission to enhance fertility care worldwide. Nexpring Health's future growth strategy includes the launch of new products designed to further enhance ART processes, with specific timelines for introducing these innovations expected in the coming years.

The company plans to expand into new markets, particularly targeting regions in Europe and Asia by mid-2026. The recent acquisitions are intended to bolster this growth, enhancing the company's capabilities and product offerings, ensuring it meets the evolving needs of its clients in the fertility sector.